

Supplement Table S2. Reasons for discontinuation of secukinumab treatment.

Reasons for secukinumab discontinuation, n (%)	Reimbursed	Non-reimbursed	All patients
Financial reasons and almost clear of lesions	0 (%)	5 (20.8%)	5 (4.2%)
Secondary loss of efficacy	5 (5.3%)	0 (0%)	5 (4.2%)
Patient decision	4 (4.3%)	0 (0%)	4 (3.3%)
Financial reasons	0 (0%)	3 (12.5%)	3 (2.5%)
Adverse events	1 (1.1%)	3 (12.5%)	4 (3.3%)
Clinical trial participation	0 (0%)	2 (8.3%)	2 (1.7%)
Unexpected death	1 (1.1%)	0 (0 %)	1 (0.8%)
Newly diagnosed with malignancy	0 (0%)	1 (4.1 %)	1 (0.8%)
Primary lack of efficacy	1 (1.1%)	0 (0%)	1 (0.8%)